不同剂量替考拉宁治疗重症医院获得性肺炎疗效观察及安全性评价

目的 观察不同剂量替考拉宁治疗重症医院获得性肺炎患者的临床疗效及安全性.方法 选取2009年10月-2011年10月的48例重症医院获得性肺炎患者作为研究对象,随机分为试验组、对照组,各24例,试验组患者应用替考拉宁400 mg,1次/12 h,静脉滴注,连续3d后,改为1次/24 h;对照组应用替考拉宁400 mg,第1天为1次/12 h,后改为1次/24 h,静脉滴注;疗程14～21 d;观察治疗前后两组患者的临床症状及体征、影像学表现、临床疗效、细菌清除率及不良反应,并对其进行分析及评价.结果 试验组患者临床有效率为83.33％,细菌清除率为79.17％,不良反应发生率为4.17％;对照组患者临床有效率为70.83％,细菌清除率为62.50％,不良反应发生率为4.17％,两组间细菌清除率及临床有效率差异有统计学意义,不良反应发生率差异无统计学意义.结论 高起始剂量替考拉宁治疗重症医院获得性肺炎疗效较好,且安全可靠.

Efficacy and safety of different doses of teicoplanin in treatment of severe hospital-acquired pneumonia

OBJECTIVE To observe the efficacy and safety of different dose of teicoplanin in the treatment of patients with severe hospital acquired pneumonia.METHODS A total of 48 severe patients with hospital acquired pneumonia,who were diagnosed in our hospital during Oct 2009-Oct 2011,were equally divided into two groups.One group was received teicoplanin 400mg twice a day,after three days,once a day in the following 14-21 days;another group was given teicoplanin 400mg twice a day in the first day,then once a day in the following 14-21 days.To observe and analysis the clinical manifestations,physical sign,imaging appearances,the clinical effects,the bacterial clearance rate and adverse reactions before and after the treatment.RESULTS The clinical efficacy rate of test group and control group was 83.33% and 70.83%.The bacterial clearance rate in two groups was 79.17% and 62.5%.The side effect rate was 4.17% and 4.17%.There were statistical differences between the two groups in clinical efficacy rate and bacterial clearance rate(P<0.05).CONCLUSION It is high effective and safe so that the initial loading dose of teicoplanin is reasonably applied in patients with severe hospital acquired pneumonia.